Findings of review into coronavirus (COVID-19) AstraZeneca vaccination published

Findings of review into coronavirus (COVID-19) AstraZeneca vaccination published

The Europeans Medicines Agency (EMA) has published the Pharmacovigilance Risk Assessment Committee's (PRAC) findings, following PRAC's review into the AstraZeneca coronavirus (COVID-19) vaccine. PRAC's review involved experts in blood disorders, and worked alongside other health authorities including the UK’s Medicines and Healthcare products Regulatory Agency. According to PRAC, the 'benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets'. PRAC confirmed that it will undertake additional review of these risks, including looking at the risks with other types of coronavirus vaccines and continue close safety monitoring of reports of blood clotting disorders.

PRAC confirmed the following:

• the benefits of the vaccine in fighting against the widespread of coronavirus continues to outweigh the risk of side effects

• 'the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it'

• there is no evidence of a issue related to certain batches of the vaccine or to particular manufacturing sites

• 'the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, ie low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (cerebral venous sinus thrombosis)'

Source: COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets

Related Articles:
Latest Articles: